Impact of baseline body mass index on the long-term prognosis of advanced hepatocellular carcinoma treated with immunotherapy
BMI is a long-term predictor of the efficacy of lenvatinib plus camrelizumab, and obese/overweight patients have a better prognosis.
Authors
- Pengfei Qu (ORCID: https://orcid.org/0000-0001-9174-3819)
- Zhiyuan Yao (ORCID: https://orcid.org/0000-0002-5759-9822)
- Zhengxiang Han (ORCID: https://orcid.org/0000-0003-2463-8933)
- Haonan Liu (ORCID: https://orcid.org/0009-0001-6518-6454)
- Jie Jiang (ORCID: https://orcid.org/0000-0002-9252-1553)
- Di Pan (ORCID: https://orcid.org/0009-0000-8992-0281)
- Wang Yu-qin (ORCID: https://orcid.org/0009-0005-7683-2377)
- Yuqi Li (ORCID: https://orcid.org/0000-0003-4629-4027)
- Qing-Hao Gu
- Run-Bang Wang
Institutions
- Xuzhou Medical College (CN)
- Suizhou Central Hospital (CN)
- Second Affiliated Hospital of Xuzhou Medical College (CN)
- Xuzhou No.1 People's Hospital (CN)
Publication Details
- Journal
- World Journal of Gastroenterology
- Published
- 2024-09-26
- DOI
- https://doi.org/10.3748/wjg.v30.i37.4132
- Citations
- 9
- Primary Topic
- Liver Disease Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 3.48
Funders
- Xuzhou Medical University